RPE65 and Leber congenital amaurosis: Luxturna (voretigene neparvovec-rzyl), an AAV2-based therapy, was a landmark treatment option for patients with biallelic loss of function mutations in RPE65, and was the first gene therapy treatment approved by the U.S. Food and Drug Administration (FDA) following demonstration of improved functional vision in previously untreatable LCA [6].